Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656851 | 0.85 | DGAT1 (0.32) | — | |
| SCHEMBL2656158 | 0.85 | ADORA2A (0.32) | — | |
| SCHEMBL2657685 | 0.84 | BTK (0.30) | — | |
| SCHEMBL2661204 | 0.83 | LCK (0.32) | — | |
| SCHEMBL2656238 | 0.83 | GRM5 (0.31) | — | |
| SCHEMBL2658826 | 0.83 | GRM5 (0.30) | — | |
| SCHEMBL2656102 | 0.82 | GABRG2 (0.34) | — | |
| SCHEMBL2657086 | 0.82 | UGCG (0.36) | — | |
| SCHEMBL2661486 | 0.82 | P2RX7 (0.30) | — | |
| SCHEMBL2658318 | 0.82 | GABRG2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | BRD4 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.